Trial Profile
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Brexucabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms ZUMA-8
- Sponsors Kite Pharma
- 24 Nov 2023 This trial has been completed in Germany (Date of the global end of the trial: 17-Nov-2022), according to the European Clinical Trials Database record.
- 31 Oct 2023 Number of treatment arms increased from 4 to 5 by the addition of Experimental: Second Stage Cohort 4B arm.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition.